NASDAQ:ORTX Orchard Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Orchard Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. $0.67 +0.03 (+4.65%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$0.65▼$0.6950-Day Range$0.42▼$0.6752-Week Range$0.41▼$4.04Volume1.92 million shsAverage Volume1.24 million shsMarket Capitalization$84.92 millionP/E RatioN/ADividend YieldN/APrice Target$7.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Orchard Therapeutics MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside1,049.0% Upside$7.75 Price TargetShort InterestHealthy1.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.95) to ($0.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.64 out of 5 starsMedical Sector884th out of 1,433 stocksBiological Products, Except Diagnostic Industry146th out of 220 stocks 3.2 Analyst's Opinion Consensus RatingOrchard Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.75, Orchard Therapeutics has a forecasted upside of 1,049.0% from its current price of $0.67.Amount of Analyst CoverageOrchard Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.13% of the float of Orchard Therapeutics has been sold short.Short Interest Ratio / Days to CoverOrchard Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Orchard Therapeutics has recently increased by 61.51%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOrchard Therapeutics does not currently pay a dividend.Dividend GrowthOrchard Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ORTX. Previous Next 1.8 News and Social Media Coverage News SentimentOrchard Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Orchard Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for ORTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Orchard Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orchard Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.34% of the stock of Orchard Therapeutics is held by insiders.Percentage Held by Institutions56.47% of the stock of Orchard Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Orchard Therapeutics are expected to grow in the coming year, from ($0.95) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Orchard Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orchard Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrchard Therapeutics has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ORTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Orchard Therapeutics (NASDAQ:ORTX) StockOrchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.Read More ORTX Stock News HeadlinesJuly 7, 2022 | msn.comIndian Orchard monthly cruise night returnsJuly 6, 2022 | marketwatch.comGlobal Orchard Tractors Market 2022 Size, Share, Applications, Advance Technology and Top Companies to 2028July 7, 2022 | Wealthy Millionaire (Ad)Big Potential Stock For 2022This hot penny stock is on the move. Put it on your radar now.July 5, 2022 | msn.comCrews battle fire on Orchard Street in PittsfieldJuly 4, 2022 | msn.comPolice issue update after man's body found in Orchard ParkJuly 3, 2022 | msn.comPolice remain at scene of tragic Orchard Park deathJuly 3, 2022 | americanbankingnews.comOrchard Therapeutics plc (NASDAQ:ORTX) Short Interest Up 61.5% in JuneJuly 2, 2022 | msn.comBody found on Orchard Park in Hull after 'unexplained' deathJuly 7, 2022 | Wealthy Millionaire (Ad)Big Potential Stock For 2022This hot penny stock is on the move. Put it on your radar now.June 30, 2022 | msn.comAir conditioner determined to be cause of fire on Orchard St. in NorthamptonJune 30, 2022 | msn.com‘Raise the Shade’ fundraises for shade structures at Old Orchard Elementary SchoolJune 29, 2022 | msn.comNorthampton 3rd floor apartment fire on Orchard StreetJune 28, 2022 | vernonmorningstar.comKelowna RCMP with guns drawn take down one man at Orchard PlazaJune 25, 2022 | msn.comTourists return to Old Orchard BeachJune 25, 2022 | msn.comA familiar face now becomes chief of Old Orchard BeachJune 23, 2022 | msn.comAugusta man wanted for questioning in reference to Circle K theft on Peach Orchard RoadJune 22, 2022 | americanbankingnews.comFinancial Analysis: Miromatrix Medical (NASDAQ:MIRO) & Orchard Therapeutics (NASDAQ:ORTX)June 19, 2022 | msn.comTwo wounded in Plum Orchard shooting, conditions unknownJune 19, 2022 | msn.comOrchard Park residents fed up with people dumping litter and 'bringing the area down'June 18, 2022 | msn.comMichigan high school baseball: Orchard Lake St. Mary's defeats GP North in Division 1, 1-0June 17, 2022 | bizjournals.com2022 Health Care Heroes: Dr. Paul Orchard develops life-saving gene therapy treatmentJune 17, 2022 | americanbankingnews.comAnalysts Set Orchard Therapeutics plc (NASDAQ:ORTX) PT at $7.75June 14, 2022 | msn.comMan killed in Plum Orchard neighborhoodJune 14, 2022 | msn.comSingapore Prime Orchard retail rents to grow by 3% this yearJune 13, 2022 | msn.comPort Orchard considers raising fees on developers to build new parksJune 11, 2022 | msn.comOrchard Park woman pleads guilty to theft of $53,000 from employerJune 9, 2022 | tmcnet.comOrchard Global Asset Management announces Danny Jeon has joined the firm as Executive Director, Head of Client Solutions-KoreaSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ORTX CUSIPN/A CIK1748907 Webwww.orchard-tx.com Phone442038088286FaxN/AEmployees259Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today7/07/2022Next Earnings (Estimated)8/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$7.75 High Stock Price Forecast$13.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+1,049.0%Consensus RatingHold Rating Score (0-4)2.33333333333333 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-144,580,000.00 Net MarginsN/A Pretax Margin-2,137.78% Return on Equity-68.98% Return on Assets-46.08% Debt Debt-to-Equity Ratio0.17 Current Ratio5.06 Quick Ratio5.06 Sales & Book Value Annual Sales$1.67 million Price / Sales50.85 Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / Book0.40Miscellaneous Outstanding Shares125,900,000Free Float121,700,000Market Cap$84.92 million OptionableNot Optionable Beta0.87 Orchard Therapeutics Frequently Asked Questions Should I buy or sell Orchard Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Orchard Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORTX, but not buy additional shares or sell existing shares. View analyst ratings for Orchard Therapeutics or view top-rated stocks. What is Orchard Therapeutics' stock price forecast for 2022? 6 brokerages have issued 1-year target prices for Orchard Therapeutics' stock. Their ORTX stock forecasts range from $4.00 to $13.00. On average, they expect Orchard Therapeutics' stock price to reach $7.75 in the next twelve months. This suggests a possible upside of 1,049.0% from the stock's current price. View analysts' price targets for Orchard Therapeutics or view top-rated stocks among Wall Street analysts. How has Orchard Therapeutics' stock price performed in 2022? Orchard Therapeutics' stock was trading at $1.32 at the start of the year. Since then, ORTX stock has decreased by 48.9% and is now trading at $0.6745. View the best growth stocks for 2022 here. When is Orchard Therapeutics' next earnings date? Orchard Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for Orchard Therapeutics. How were Orchard Therapeutics' earnings last quarter? Orchard Therapeutics plc (NASDAQ:ORTX) announced its quarterly earnings results on Thursday, May, 12th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.10. The company earned $5.52 million during the quarter, compared to the consensus estimate of $4.97 million. View Orchard Therapeutics' earnings history. Who are Orchard Therapeutics' key executives? Orchard Therapeutics' management team includes the following people: Dr. Bobby Gaspar M.D., Ph.D., CEO, Member of Scientific Advisory Board & Exec. Director (Age 58, Pay $850.18k)Mr. Frank E. Thomas, Pres & COO (Age 52, Pay $716.6k)Dr. Nicoletta Loggia Ph.D., Chief Technical OfficerDr. Fulvio Mavilio Ph.D., Chief Scientific OfficerMs. Renee T. Leck, Director of Investor RelationsBenjamin Navon, Director of Corp. CommunicationsMr. John Cerio, Chief Human Resource OfficerDr. Anne Dupraz-Poiseau, Chief Devel. OfficerMr. Robin Kenselaar, Sr. VP & GM of EMEA Commercial OperationsMr. Braden Parker, Chief Commercial Officer Who are some of Orchard Therapeutics' key competitors? Some companies that are related to Orchard Therapeutics include DBV Technologies (DBVT), Vickers Vantage Corp. I (VCKA), AlloVir (ALVR), Icosavax (ICVX), Eiger BioPharmaceuticals (EIGR), Lineage Cell Therapeutics (LCTX), Opthea (OPT), Compass Therapeutics (CMPX), Adaptimmune Therapeutics (ADAP), Sutro Biopharma (STRO), GreenLight Biosciences (GRNA), Autolus Therapeutics (AUTL), Outlook Therapeutics (OTLK), Voyager Therapeutics (VYGR) and SOPHiA GENETICS (SOPH). View all of ORTX's competitors. What other stocks do shareholders of Orchard Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), (NGM), Selecta Biosciences (SELB) and VBI Vaccines (VBIV). When did Orchard Therapeutics IPO? (ORTX) raised $200 million in an initial public offering on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Orchard Therapeutics' stock symbol? Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX." How do I buy shares of Orchard Therapeutics? Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Orchard Therapeutics' stock price today? One share of ORTX stock can currently be purchased for approximately $0.67. How much money does Orchard Therapeutics make? Orchard Therapeutics (NASDAQ:ORTX) has a market capitalization of $84.92 million and generates $1.67 million in revenue each year. The company earns $-144,580,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. How many employees does Orchard Therapeutics have? Orchard Therapeutics employs 259 workers across the globe. How can I contact Orchard Therapeutics? Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The official website for Orchard Therapeutics is www.orchard-tx.com. The company can be reached via phone at 442038088286. This page (NASDAQ:ORTX) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
